Effectiveness of SARS-CoV-2 vaccination in liver transplanted patients: The debate is open!
作者信息
Guarino Maria, Cossiga Valentina, Esposito Ilaria, Furno Alessandro, Morisco Filomena
机构信息
Department of Clinical Medicine and Surgery, Gastroenterology and Hepatology Unit, University of Naples "Federico II", Naples, Italy.
Department of Clinical Medicine and Surgery, Gastroenterology and Hepatology Unit, University of Naples "Federico II", Naples, Italy.
出版信息
J Hepatol. 2022 Jan;76(1):237-239. doi: 10.1016/j.jhep.2021.07.034. Epub 2021 Aug 3.
Abstract
摘要
相似文献
1
Effectiveness of SARS-CoV-2 vaccination in liver transplanted patients: The debate is open!严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）疫苗在肝移植患者中的有效性：争论仍在继续！
J Hepatol. 2022 Jan;76(1):237-239. doi: 10.1016/j.jhep.2021.07.034. Epub 2021 Aug 3.
2
Reply to: "Effectiveness of SARS-CoV-2 vaccination in liver transplanted patients: The debate is open!".回复：“严重急性呼吸综合征冠状病毒2型疫苗在肝移植患者中的有效性：争论仍在继续！”
J Hepatol. 2022 Jan;76(1):239-240. doi: 10.1016/j.jhep.2021.09.037. Epub 2021 Oct 8.
3
COVID-19 vaccination immune paresis in heart and lung transplantation.新型冠状病毒肺炎疫苗接种在心肺移植中的免疫麻痹
J Heart Lung Transplant. 2021 Aug;40(8):763-766. doi: 10.1016/j.healun.2021.04.018. Epub 2021 May 13.
4
Acceptance of SARS-CoV-2 vaccines by liver transplant recipients and candidates.肝移植受者和候选者对 SARS-CoV-2 疫苗的接受情况。
Z Gastroenterol. 2021 Dec;59(12):1288-1296. doi: 10.1055/a-1649-8568. Epub 2021 Oct 20.
5
Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.辉瑞-生物科技和 Moderna 疫苗在 SARS-CoV-2 B.1.617.2（Delta）变异株广泛传播之前和期间预防养老院居民感染 SARS-CoV-2 的有效性 - 国家医疗保健安全网络，2021 年 3 月 1 日至 8 月 1 日。
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1163-1166. doi: 10.15585/mmwr.mm7034e3.
6
Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.辉瑞/生物科技和牛津/阿斯利康疫苗对沙特阿拉伯全国疫苗接种运动中真实环境下 COVID-19 发病率和死亡率的影响。
Eur Rev Med Pharmacol Sci. 2021 Nov;25(22):7185-7191. doi: 10.26355/eurrev_202111_27271.
7
Antibody response to SARS-CoV-2 vaccination, previous SARS-CoV-2 infection, and change to single-dose vaccination.对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗接种、既往SARS-CoV-2感染的抗体反应以及改为单剂量接种。
J Med Virol. 2021 Dec;93(12):6474. doi: 10.1002/jmv.27263. Epub 2021 Aug 12.
8
[Rapid guideline for COVID-19 vaccination in patients with chronic liver diseases, hepatolbiliary malignancy and liver transplant].[慢性肝病、肝胆恶性肿瘤及肝移植患者COVID-19疫苗接种快速指南]
Zhonghua Gan Zang Bing Za Zhi. 2021 Jun 20;29(6):523-526. doi: 10.3760/cma.j.cn501113-20210612-00278.
9
SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status - Los Angeles County, California, May 1-July 25, 2021.2021 年 5 月 1 日至 7 月 25 日，加利福尼亚州洛杉矶县≥16 岁人群中，根据疫苗接种状况划分的 SARS-CoV-2 感染和住院情况。
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1170-1176. doi: 10.15585/mmwr.mm7034e5.
10
SARS-CoV-2 infection long time after full vaccination is related to a lack of neutralizing antibodies.新冠病毒（SARS-CoV-2）感染发生在完全接种疫苗很长时间后，与中和抗体缺乏有关。
Diagn Microbiol Infect Dis. 2022 Jan;102(1):115565. doi: 10.1016/j.diagmicrobio.2021.115565. Epub 2021 Oct 2.
引用本文的文献
1
High Rate of Antibody Response to Multiple Doses of the COVID-19 Vaccine in Liver Transplant Recipients: Analysis of Predictive Factors.肝移植受者对多剂新冠疫苗的高抗体反应率：预测因素分析
Vaccines (Basel). 2025 Mar 26;13(4):352. doi: 10.3390/vaccines13040352.
2
How does geographical diversity shape vaccine efficacy?地理多样性如何影响疫苗效力？
Clin Exp Vaccine Res. 2024 Oct;13(4):271-300. doi: 10.7774/cevr.2024.13.4.271. Epub 2024 Oct 31.
3
Seroconversion and safety of Covid-19 vaccines in pa-tients with chronic liver disease and liver transplant: A systematic review.新型冠状病毒肺炎疫苗在慢性肝病和肝移植患者中的血清学转换及安全性：一项系统评价。
Qatar Med J. 2023 Dec 12;2023(3):21. doi: 10.5339/qmj.2023.21. eCollection 2023.
4
Clinical Course, Immunogenicity, and Efficacy of BNT162b2 mRNA Vaccination Against SARS-CoV-2 Infection in Liver Transplant Recipients.BNT162b2 mRNA疫苗接种对肝移植受者预防SARS-CoV-2感染的临床病程、免疫原性和疗效
Transplant Direct. 2023 Sep 20;9(10):e1537. doi: 10.1097/TXD.0000000000001537. eCollection 2023 Oct.
5
The Cellular and Humoral Immune Response to SARS-CoV-2 Messenger RNA Vaccines Is Significantly Better in Liver Transplant Patients Compared with Kidney Transplant Patients.与肾移植患者相比，肝移植患者对严重急性呼吸综合征冠状病毒2信使核糖核酸疫苗的细胞免疫和体液免疫反应明显更好。
Pathogens. 2023 Jul 5;12(7):910. doi: 10.3390/pathogens12070910.
6
Clinical Outcomes of SARS-CoV-2 Breakthrough Infections in Liver Transplant Recipients during the Omicron Wave.奥密克戎变异株流行期间肝移植受者感染 SARS-CoV-2 的临床转归
Viruses. 2023 Jan 20;15(2):297. doi: 10.3390/v15020297.
7
Boosting compromised SARS-CoV-2-specific immunity with mRNA vaccination in liver transplant recipients.mRNA 疫苗接种增强肝移植受者受损的 SARS-CoV-2 特异性免疫。
J Hepatol. 2023 May;78(5):1017-1027. doi: 10.1016/j.jhep.2023.02.007. Epub 2023 Feb 18.
8
SARS-CoV-2 BA.2 (Omicron) variant infection in pediatric liver transplanted recipients and cohabitants during 2022 Shanghai outbreak: a prospective cohort.2022 年上海疫情期间，小儿肝移植受者及其同住者感染 SARS-CoV-2 BA.2（奥密克戎）变异株的前瞻性队列研究。
Virol J. 2023 Feb 11;20(1):28. doi: 10.1186/s12985-023-01978-4.
9
Immune Response after the Fourth Dose of SARS-CoV-2 mRNA Vaccine Compared to Natural Infection in Three Doses' Vaccinated Solid Organ Transplant Recipients.接种三剂 SARS-CoV-2 mRNA 疫苗的实体器官移植受者与自然感染相比的第四剂后免疫反应。
Viruses. 2022 Oct 19;14(10):2299. doi: 10.3390/v14102299.
10
Liver transplantation during COVID-19: Adaptive measures with future significance.2019冠状病毒病期间的肝移植：具有未来意义的适应性措施
World J Transplant. 2022 Sep 18;12(9):288-298. doi: 10.5500/wjt.v12.i9.288.
Zotero 插件